Maximize the chances of pregnancy without losing valuable embryos
ERA is the only endometrial receptivity test supported by a RCT*.
3 in every 10 women have their a displaced implantation window shifted**
Launched in 2011, ERA was the first test of its kind, revolutionising endometrial diagnostics and laying the foundation for personalised fertility treatment. By identifying a woman’s unique window of implantation, it enables precise embryo transfer timing to optimise IVF success. Backed by robust clinitcal evidence, ERA remains the most advanced and trusted endometrial receptivity test available.
ERA is a proven solution for patients with RIF, powered by the most
scientific publications and the highest clinical success rates compared to any other endometrial receptivity test in the market. In fact, ERA is the only endometrial receptivity test backed by an RCT*. This RCT, involving 320 patients with RIF, demonstrated significantly improved reproductive outcomes—including nearly double the live birth rates—for patients who used ERA in combination with PGT-A, compared to those who used PGT-A alone.
Powered by AI, the ERA algorithm is not only based upon the endometrial biopsy data from over 200,000 women but integrates clinical outcomes from personalised embryo transfers guided by its results. Combining this with the most comprehensive gene panel available (248 genes), ERA delivers the most precise transcriptomic profiling and personalized
embryo transfer timing—maximising implantation success.
Backed by a global team of endometrial experts, ERA is the trusted endometrial receptivity test used by over 3,000 clinics worldwide. Our comprehensive support network includes world-class scientific advisors, dedicated endometrial specialists, genetic counsellors, and in-house
clinicians—providing expert guidance to clinics and patients every step of the way.
* 2024 Barbakadze et al. Cureus 16(6): e62949. DOI 10.7759/cureus.62949
ERA® test is indicated for patients with recurrent implantation failure
90 % of cases don’t need a second biopsy. The second biopsy is only required under two circumstances:
References:
* Barbakadze et al., Assessment of theRole of Endometrial ReceptivityAnalysis in Enhancing AssistedReproductive Technology Outcomesfor Advanced-Age Patients. Cureus vol.16,6 e62949. 23 Jun. 2024,doi:10.7759/cureus.62949.
Key Studies:
Visit the ERA insight Hub – International to download the complete ERA Publication List and explore all related studies
Barbakadze T, Shervashidze M, Charkviani T, et al.
Cureus. 2024;16(6):e62949. Published 2024 Jun 23. doi:10.7759/cureus.62949
Liu Z, Liu X, Wang M, Zhao H, He S, Lai S. et al
Front Physiol. 2022;13:841437. Published 2022 Apr 27. doi:10.3389/fphys.2022.841437
Jia Y, Sha Y, Qiu Z, Guo Y, Tan A, Huang Y. et al
Med Sci Monit. 2022;28:e935634. Published 2022 Mar 22. doi:10.12659/MSM.935634
Role of endometrial receptivity array in current implantation failure.
Samadhiya R, Swarnkar G, Singh A, Chittawar P.
Fertility Science and Research, 8(2), 180
Ruiz-Alonso, M., Gómez, C., Stankewicz, T. et al.
Scientific reports vol. 15,1 16967. 15 May. 2025, doi:10.1038/s41598-025-01056-5
Simón, C., Gómez, C., Cabanillas, S., Vladimirov, I., Castillón, G., Giles, et al.
Reproductive BioMedicine Online, 2020; 41(3):402-415
Ruiz-Alonso M, Blesa D, Díaz-Gimeno P, Gómez E, Fernández-Sánchez M, Carranza F, Carrera J, Vilella F, Pellicer A, Simón C.
Fertil Steril. 2013 Sep;100(3):818-24. doi: 10.1016/j.fertnstert.2013.05.004. Epub 2013 Jun 4. PMID:23756099
Díaz-Gimeno P, Ruiz-Alonso M, Blesa D, Bosch N, Martínez-Conejero JA, Alamá P, Garrido N, Pellicer A, Simón C.
Fertil Steril. 2013 Feb;99(2):508-17. doi: 10.1016/j.fertnstert.2012.09.046. Epub 2012 Oct 23. PMID:23102856
A genomic diagnostic tool for human endometrial receptivity based on the transcriptomic signature.
Díaz-Gimeno P, Horcajadas JA, Martínez-Conejero JA, Esteban FJ, Alamá P, Pellicer A, Simón C.
Fertil Steril. 2011 Jan;95(1):50-60, 60.e1-15. doi: 10.1016/j.fertnstert.2010.04.063. Epub 2010 Jul 8. PMID:20619403
